Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Peters, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peters, A. M.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 463-470
© 2000 British Society for Rheumatology

Review

Nuclear medicine in vasculitis

Vasculitis/Series Editor: R. Watts

A. M. Peters

Department of Nuclear Medicine, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK

The first 150 words of the full text of this article appear below.

Nuclear medicine has several roles to play in the management of patients with systemic vasculitis. They can be subdivided as follows:

(1) in vitro sample counting such as for the determination of glomerular filtration rate (GFR) in patients with suspected renal impairment;
(2) non-specific imaging of ischaemic and inflammatory complications of vasculitis, such as ventilation/perfusion lung scanning in patients with involvement of medium-sized and large pulmonary arteries, and brain perfusion imaging in patients with cerebral vasculitis;
(3) specific imaging of inflammation using radioactive agents that specifically target a component of the inflammatory process, in order to
(a) help occasionally make the diagnosis in a patient presenting with non-specific symptoms and equivocal serology;
(b) define the distribution of inflammatory lesions;
(c) monitor the response of inflammatory lesions to treatment;

(4) the use of radioactive agents to improve our understanding of the pathophysiology of vasculitic diseases.

The measurement of GFR is now . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?